Dent Neurosciences Research — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$250,483	56
2024	Research	$195,059	44
2023	Research	$116,564	15
2022	Research	$164,678	31
2021	Research	$162,612	26
2020	Research	$409,018	62
2019	Research	$386,654	43

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $659,279 127 payments
Allergan Inc. $584,189 84 payments
H. Lundbeck A S $221,708 28 payments
Adamas Pharmaceuticals, Inc. $112,173 24 payments
Teva Pharmaceuticals USA, Inc. $87,878 8 payments
Argenx US, Inc. $17,840 5 payments
Amneal Pharmaceuticals LLC $2,000 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $173,762 16 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine $157,988 19 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Treatment of Migraine When Adminstered During the Premonitory Phase $127,350 12 payments
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine $125,401 13 payments
A Parallel Group, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing An Acute Attack of Migraine $108,500 10 payments
A 3-Arm Multicenter Double-Blind Placebo-Controlled Randomized Study to Assess the Efficacy and Safety of Ads-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment $95,730 18 payments
A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments $87,878 8 payments
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) $76,101 15 payments
Evaluate Efficacy & Safety of Eptinezumab Administered Intravenously in Subjects Experiencing Acute Attack of Migraine (RELIEF) $74,434 3 payments
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine $70,809 17 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.